While the expression of CDH1 was dramatically elevated in the tumor as compared to normal (Figures 7A, 7B), the GEPIA software was utilized to further validate this, using data from 492 prostate cancer patients and 152 healthy controls. Here, CDH1 is linked to prostate carcinoma.